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Abstract
Background. Pauci-immune renal vasculitis with focal
glomerular necrosis and crescent formation is usually
associated with anti-neutrophil cytoplasmic antibodies
(ANCAs). However, ANCA’s are absent in up to 10%
of cases, which constitutes a rarely studied variant of
renal vasculitis.
Methods. This retrospective multicentre cohort study
analyzed the presenting features, renal histology and
outcome in 20 patients with pauci-immune crescentic
necrotizing renal vasculitis in whom indirect immuno-
ﬂuorescence did not detect ANCA.
Results. Renal histology revealed a high percentage
of active glomerular lesions (50%), mainly cellular
crescents, 28% of them with glomerular necrosis.
Chronic tissue damage with glomerulosclerosis (21%)
and diffuse interstitial ﬁbrosis (40%) was already
present at diagnosis, more prominent than in
historical PR3-positive patients. Inﬁltrates of poly-
morphonuclear neutrophils in glomerular capillary
loops were observed in 40% of all biopsies, mainly in
necrotic lesions. The subsets of interstitially inﬁltrat-
ing leukocytes similar to ANCA-associated disease.
Microscopic polyangiitis was diagnosed in 17 patients,
Wegener’s granulomatosis in two and renal-limited
vasculitis in one. The patients median disease extent
index (DEI) of 5 (range 4–11) reﬂected a systemic
vasculitis. ANCA-negative vasculitis was not asso-
ciated with infection or malignancy. Renal outcome
was correlated to DEI (P¼ 0.032) and serum creati-
nine at diagnosis (P¼ 0.04). The mortality rate was
high (35%) and closely related to age above 65 years
at diagnosis (P¼ 0.014).
Conclusions. The histological ﬁndings and prognosis
in ANCA-negative renal vasculitis are comparable
with those of ANCA-positive disease. Our data
underline the importance of the exact diagnosis in an
active vasculitic disease process even in the absence of
ANCAs.
Keywords: ANCA-negative; microscopic polyangiitis;
neutrophils; pauci-immune renal vasculitis; renal
biopsy; renal outcome; Wegener’s granulomatosis
Introduction
Pauci-immune crescentic necrotizing glomerulonephri-
tis (GN) is deﬁned histologically by the presence of
focal glomerular necrosis and extracapillary prolifera-
tion in the absence of signiﬁcant glomerular immune
deposits. This type of GN, which represents a frequent
cause of acute renal failure, is due to small vessel
vasculitis. It occurs during systemic diseases such as
microscopic polyangiitis (MPA), Wegener’s granulo-
matosis (WG) and more rarely Churg–Strauss
syndrome or as a renal-limited vasculitis (RLV) [1].
The association of anti-neutrophil cytoplasmic
antibodies (ANCAs) with WG, described in 1985 [2],
was a major step in distinguishing pauci-immune
crescentic necrotizing GN from other types of rapidly
progressive GN, e.g. post-infectious, cryglobulinaemic,
anti-glomerular basement membrane, IgA nephrop-
athy and lupus nephritis.
Indirect immunoﬂuorescence (IIF) [p-ANCA for
myeloperoxidase (MPO); c-ANCA for proteinase 3
(PR3)] is highly sensitive to identify ANCA, in active
untreated WG or MPA, with a positive test in
>75–90% of patients [3–5]. Because of the strong
association between disease and ANCA’s, numerous
studies have proposed a pathogenic role for ANCAs in
the development of vasculitis involving small vessels [6].
However, in a signiﬁcant number of cases of pauci-
immune crescentic GN, ANCAs are absent. Earlier
studies, comparing those with ANCA-positive cases
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suffer, because ANCA-negative groups are small or
heterogeneously deﬁned [3,7]. Therefore, we describe
the clinical course, histological features and outcome
in 20 patients with pauci-immune crescentic GN and
a consistently negative test for ANCA.
These results will be compared to existing data of
an ANCA-positive cohort.
Patients and methods
Patients and selection criteria
This retrospective study identiﬁed 20 patients who pre-
sented between 1990 and 2001 with a pauci-immune crescentic
necrotizing GN and in whom no evidence for circulating
ANCAs was found by immunoﬂuorescence (IF) testing. The
patient recruitment was performed in collaboration with
pathologists and clinicians in three French hospitals from a
cohort of 625 patients with ANCA-associated vasculitis
(17% anti-PR3/79% anti-MPO). In each patient, a renal
biopsy had been performed at the time of diagnosis, and it
was analysed for the purpose of this study. All patients’
records were reviewed and relevant data were extracted.
Immunological data
Testing for ANCA was performed by IIF in ethanol-ﬁxed
neutrophils at initial clinical presentation and was obtained
regularly during follow-up, particularly during relapses of
vasculitis. Before 1997, ANCA tests were performed using
an in-house method. After 1997, we used a commercial
kit (Euroimmun, Germany, distributed by Bioadvance in
France).
Tests for anti-MPO and anti-PR3 antibodies were per-
formed in all sera available by enzyme-linked immuno-
sorbent assay (ELISA; Euroimmun, Germany). In addition,
in four cases (two WG, two MPA), a capture-ELISA
technique (performed in the laboratory of A. Wiik) was
used to conﬁrm ANCA negativity. Other immunological
markers are reported if performed.
Clinical data
Acute renal insufﬁciency was deﬁned as an increase of at
least 30% of baseline serum creatinine in <3 months. The
glomerular ﬁltration rate (GFR) was calculated using the
Cockcroft–Gault formula, considering the highest initial
creatinine at diagnosis and the latest available creatinine
value during follow-up. Nephrotic syndrome was deﬁned as
proteinuria >3.5 g/day and a serum albumin <30 g/l. Arterial
hypertension was deﬁned as a blood pressure >140/90mmHg
or if antihypertensive medication was needed. MPA, WG
and RLV were diagnosed according to the Chapel-Hill
consensus conference criteria [8]. For classiﬁcation purposes,
chest and or sinus X-ray results were evaluated from all
patients. Additionally, the results of any biopsy of extra-renal
organs were considered.
Disease activity at initial clinical presentation was
evaluated by using the Birmingham Vasculitis Assessment
Score (BVAS) [9]. Brieﬂy, the BVAS consists of a list of items
that are predominantly based on clinical history and
examination, supported by certain laboratory data such as
serum creatinine and the presence and absence of blood
or protein in the urine. Vasculitis-related organ involvement
was assessed using the disease extent index (DEI) [10].
Renal biopsies
Parafﬁn-embedded renal sections were stained with
trichrome, silver, periodic acid–Schiff and haematoxylin/
eosin. IF microscopy results were available for all patients
included in the study. The IF studies were performed by a
classic direct IF technique using antibodies against IgA, IgG,
IgM, C3, C1q, ﬁbrin, albumin, and k and l light chain. The
tested antisera either did not stain or the staining was
scattered and thus were insufﬁcient to suggest any main
diagnosis other than pauci-immune crescentic GN.
All biopsies were reviewed by one experienced pathologist
(L.H.N.) and renal lesions representative of disease activity
and chronicity were scored using a standardized protocol
for ANCA-associated systemic vasculitis as reported else-
where [11]. These results were compared with existing
historical data on ANCA-positive pauci-immune renal
vasculitis [7] which were evaluated by the same histological
scoring system.
In short, each glomerulus was scored separately for
the presence or absence of ﬁbrinoid necrosis, crescents
(cellular-segmental, cellular-circumferential, ﬁbrous) and
global sclerosis. The number of glomeruli revealing these
lesions was expressed as the percentage of the total number of
glomeruli (100%) in the biopsy. The percentage of normal
glomeruli was scored as well.
Other lesions were scored semi-quantitatively as
mesangial proliferation, capillary loop inﬁltrates (0¼<5,
1¼>5 inﬂammatory cells per glomerulus), interstitial inﬁl-
trates (0¼ absent, 1¼<20%, 2¼ 20–50%, 3¼>50%) and
interstitial ﬁbrosis (0¼ absent, 1¼ focal, 2¼ diffuse).
To assess cellular tissue inﬁltration, T cells and macro-
phages were stained immunohistochemically with, respec-
tively anti-CD3 (dilution 1/300) and anti-CD68 (dilution
1/1000) (Dako) and were compared. Neutrophil cell inﬁltra-
tion (PN) per glomerular section or per interstitial inﬁltrate
was calculated by the characteristic nuclear morphology.
Arteries and arterioles were evaluated for the presence of
vasculitis, arterial hyalinosis or sclerosis.
Statistics
All statistical analyses were carried out using the
SPSS package for windows. Descriptive statistics were
performed with standard tests. Kaplan–Meier curves were
used to evaluate the inﬂuence of histological and selected
clinical parameters on survival; the signiﬁcance level was
tested by log-rank. To identify variables predictive of renal
outcome at follow-up, partial correlation for GFR change
during follow-up adjusted to age was tested for histological
and clinical parameters (two-tailed, signiﬁcance level
P 0.05).
Results
Twenty patients were identiﬁed (15 males and ﬁve
females) with a median age of 65 years at presentation
(range 33–82 years).
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Renal involvement (Table 1)
The majority of patients presented with acute renal
insufﬁciency (17 out of 20 patients). Six of them showed
acute renal failure with a creatinine >500 mmol/l;
four required short-term haemodialysis at diagnosis
(1–2 weeks). Median serum creatinine at presentation
was 267.5 mmol/l (range 62–1219). Microhaematuria
was present in all cases. The median level of protein-
uria was 2.7 g/day (range 0.44–11). Nephrotic syn-
drome was present in four cases. Of the 20 patients, 11
were hypertensive. The median time between the
appearance of ﬁrst symptoms and renal biopsy was
2 months (range 0.5–36).
Extra-renal involvement
Seventeen out of 20 patients showed constitutional
symptoms of vasculitis including fatigue, night sweats,
weight loss and fever. Myalgia or arthralgia or both,
were present in eight patients, and biopsy-proven
muscle vasculitis in one. Clinical signs of vasculitic
skin involvement were observed in 10 cases, and
biopsy-proven skin vasculitis in seven. Sinusitis or
rhinitis or both, associated with epistaxis in one, was
judged as ENT involvement in four patients, corre-
sponding histologically to giant cell granuloma in one
and to non-speciﬁc inﬂammation in two patients.
Pulmonary inﬁltrates revealed by X-ray were seen
in three cases, with cavitated nodules in two. Pericardial
effusion with histological signs of inﬂammation and
haemodynamic depression, necessitating drainage, was
present in two patients, and minor effusion was present
in one other patient. Ischaemic bowel disease was
present in two cases. Three cases had neurological
involvement in the form of peripheral neuropathy.
Intracerebral haematoma was considered to be an
initial clinical sign of vasculitis in patient 7, without any
angiographic evidence of aneurism formation.
Altogether, in 11 patients extrarenal biopsies
showed vasculitis. The median BVAS score was 18.5
(range 14–29). The median DEI score was 5 (range
4–11), representing the involvement of at least two
organs.
Diagnostic classiﬁcation
MPA was diagnosed in 17 out of 20 patients. Two
patients were classiﬁed as WG (patients 1 and 7) and
one patient as RLV (patient 2).
Concomitant diseases
Monoclonal gammopathy of undetermined signiﬁ-
cance was diagnosed in patients 5 and 14. Patient 4
had an alcohol-induced cirrhosis without signs of
portal hypertension at initial presentation. Two
patients had pulmonary embolism (patient 1 after the
diagnosis of vasculitis and patient 3 a few weeks
before). No medication known to induce a vasculitis
has been identiﬁed retrospectively in the cohort.
Infection with hepatitis B or C, nor any other virus,
nor a concomitant neoplasia was observed.
Immunology
IF testing for ANCAs was negative in all patients
at diagnosis, before the initiation of immunosuppres-
sive therapy, and remained negative during follow-up.
ELISA tests for anti-MPO or anti-PR3 or both were
negative in all 11 tested patients. In all WG patients,
additionally performed capture-ELISAs were negative.
Anti-nuclear antibodies were positive in three patients
out of 19, whereas anti-DNA antibodies were not
detected in any of the patients (see Table 1). Anti-
phospholipid antibodies were positive (low range titre)
in three out of 11 patients, and lupus anticoagulant was
absent in four tested patients. Anti-GBM antibodies
were negative in ﬁve tested patients. Cryoglobulinaemia
was detected in three out of 16 patients, associated with
a monoclonal gammopathy in one. Serum complement
component levels were normal in all patients (data not
shown).
Renal histology
Fifty percent of glomeruli had (predominantly
cellular) crescents, 21% were globally sclerotic and
29% were normal (Table 2). Fibrinoid necrosis of
the glomerular tuft was present in 28% of glomeruli
with crescents. In two biopsies, necrosis was present
in glomeruli without crescents. Mild capillary loop
inﬁltration was observed in 75% of all biopsies,
partly with the presence of polymorphonuclear cells.
In ﬁve patients, polymorphonuclear neutrophils were
observed in necrotic lesions. In three other patients,
they were also present in the capillary lumen (more
than ﬁve neutrophils per glomerulus), though this
inﬁltration was irregularly distributed amongst the
glomeruli.
Interstitial ﬁbrosis was present in 80% of biopsies
and, in half of these cases, it was scored as diffuse.
Interstitial inﬁltrates were seen in 95% of all biopsies,
being moderate or intense in 45%. In the later case,
cellular typing revealed a mixed inﬁltrate of lympho-
cytes (CD3-positive), macrophages (CD68-positive)
and PNs. Hyalinosis and arteriolosclerosis were present
in 45 and 40% of all biopsies, respectively.
IF studies showed the absence of signiﬁcant immune
deposits in all but two patients. In case 7, IF studies
showed rare irregular epimembranous IgG deposits
in glomerular focal necrosis and crescents. In case 20,
mild irregular glomerular C3 deposits were present
on the initial biopsy. However, these deposits were
absent in two subsequent biopsies performed because
of persistent clinical disease. In two biopsies, giant cells
(patients 1 and 15) were found, in patient 1 in combi-
nation with vascular granuloma.
Three patients had follow-up biopsies (time inter-
val 6–12 months after initial biopsy), which revealed
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active lesions in two as signs of persistent disease or
relapse and predominantly chronic lesions in one
patient.
Treatment
The majority of patients (16 out of 20) received a
primary immunosuppressive protocol with oral and
with or without intravenous steroids, and cyclophos-
phamide pulse therapy. Patient 8 had plasma exchange.
Patient 19 received high doses oral prednisone and oral
trimethoprim/sulfamethoxazole.
Three patients were treated initially with
steroids only: patients 14 and 18 because of their age
and patient 20 as it was post-infectious GN that was
suspected initially. After a period of 6–12 months,
cyclophosphamide was substituted by azathioprine in
two patients, and by trimethoprim/sulfamethoxazole
in one. Ten patients received low-dose steroid main-
tenance therapy only (median duration: 18 months,
range 4–24).
Outcome
Survival was signiﬁcantly determined by age at
diagnosis (see Figure 1). Seven patients (35%) died,
all in the ﬁrst year following the diagnosis of vasculitis
(median age 76.6 years vs 56.2 years in long-term
surviving patients). Causes of death were myocardial
infarction in two, septic shock in two and intestinal
haemorrhage due to uncontrolled vasculitis in one
patient. In two patients, the cause of death remained
undetermined. In three cases, renal function improved
prior to death.
Renal outcome was deﬁned as the change of GFR
during follow-up. Median GFR at the latest visit was
26ml/min (range 4–49.5). Only one patient progressed
to end-stage renal failure.
Initial creatinine and the DEI were signiﬁcantly
correlated with renal function change, adjusted for age
(r¼0.49, P¼ 0.042; r¼ 0.47, P¼ 0.032). Histological
scores, like the percentage of normal glomeruli
(r¼ 0.07, P¼ 0.77), crescents (r¼ 0.10, P¼ 0.67) or
glomerular necrosis (r¼ 0.41, P¼ 0.085), did not
correlate with renal outcome.
Relapse of disease requiring the reintroduction or an
increase of immunosuppressive therapy occurred in
20% of all patients, with renal involvement in four
out of ﬁve cases. The median time interval between
diagnosis and relapse was 8.5 months (range 4–12).
Discussion
Pauci-immune necrotizing small vessel vasculitis is
usually associated with the presence of ANCAs
directed to proteinase 3 (PR3-ANCA) or myeloperoxi-
dase (MPO-ANCA) [1,2].
Table 2. Glomerular and interstitial lesions at initial biopsy of 20 ANCA-negative patients
Glomerular lesions Interstitial lesions
n±SD % Grading (% of all biopsies)
0 1 2 3
No. of glomeruli/biopsy 17±13.1 100 Fibrosis 20 40 40 –
Normal glomeruli 5±3.9 29.4 Cellular inﬁltration 5 50 30 15
Glomerular sclerosis 3.6±3.7 20.9
Crescents 8.4±11.5 49.7 Cellular inﬁltration 0/1 2/3
Cellular circumferential 4.1±10.3 24.1 Subtype
Cellular segmental 2.7±2.2 15.9 PN <5 10/11 2/9
Fibrotic 1.6±3.4 9.1 PN >5 1/11 7/9
Necrotic glomeruli 8.4±10.3 28.5 Typea
Capillary loop inﬁltration – 80 CD68¼CD3 – 5/9
PN inﬁltrates CD68<CD3 – 2/9
<5/glomerulus – 70 CD68>CD3 – 1/9
>5/glomerulus – 30
aOnly cellular inﬁltrates grade 2–3 were assessed for CD68 and CD3 staining.
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Fig. 1. Patient survival was dependent on age at diagnosis in
ANCA-negative vasculitis. Median patient age of 65 years
dichotomized the two groups (P<0.014; n¼ 10 for each group).
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More rarely ANCA’s are absent in this type of
vasculitis [12,13]. In WG, ANCAs may remain negative
in the limited ENT form (granulomata) of the disease.
However, ANCAs are usually detected when the
disease progresses to a systemic vasculitic stage [14].
Published data regarding kidney involvement and
outcome in ANCA-negative pauci-immune vasculitis
are scarce and often lack a clear-cut proof of ANCA
negativity [3,7]. One of the reasons is the difﬁculty
of establishing the absence of ANCAs. We analyzed
only patients with consistently negative ANCAs on IIF.
As recommended by the international consensus
conference, we used IIF as ﬁrst line diagnostic tool,
because of its high sensitivity for detecting ANCAs
[5,15,16]. Although the false-negative rate of IIF is
relatively low [16], we have conﬁrmed negative IIF
by speciﬁc ELISAs for anti-PR3 and anti-MPO in the
majority of patients.
In our ANCA-negative patients, there is a clear
predominance of patients with MPA (85%). This
ﬁnding could be related to the high incidence rate of
MPA among pauci-immune vasculitis in Southern
Europe [17], whereas WG is much more common in
Northern Europe [18]. On the other hand, a Swedish
vasculitis case-ﬁnding study [19], which considered
only patients from a nephrology department, found
more cases of MPA (79%) than WG (21%) in their
cohort. Therefore, we cannot rule out that the
predominance of MPA in our study group reﬂects
selection bias.
ANCA-negative pauci-immune GN is part of a
systemic vasculitic disease process. The latter usually
involves additionally at least one extra-renal organ
system as shown by the high DEI score of 5 for our
comparable with cohort, a score comparable with that
of ANCA-positive vasculitis [10]. Nearly all our
patients presented with constitutional symptoms.
Interestingly, we observed a high prevalence of extra-
renal signs of skin (50%), joint and muscle (40%)
involvement. Only a minor percentage presented with
ENT and pulmonary symptoms. In an earlier study of
98 patients with ANCA-associated vasculitis [4], ENT
and lung involvement was predominant, with a high
prevalence of pulmonary haemorrhage (40%) in MPO-
positive patients.
Renal vasculitic involvement presented with typical
clinical signs in our ANCA-negative cohort. The
absence of deposits in IF studies of renal biopsies
excluded a post-infectious or immune complex origins
of the disease. Scant deposits were observed in
two patients. Patient 20 presented a C3 positivity for
IF, which disappeared on two subsequent biopsies
taken during persistent clinical disease activity, and
patient 7 had segmental epimembranous deposits with
a nephrotic syndrome at diagnosis. The coincidence
of crescentic GN and membranous nephropathy is
rarely observed. Tse et al. described 10 cases of mem-
branous nephropathy complicated by vasculitic glo-
merulonephropathy with negative ANCA tests in ﬁve
cases [20]. They observed a more aggressive clinical
course than in membranous nephropathy alone.
Active renal disease was evident in all kidney biopsies
in the present series.
We compared our ﬁndings to those of 58 MPO-
ANCA-positive and 63 PR3-ANCA-positive patients
of a recent multicentre study from the EUVAS
(European vasculitis) network, using identical histo-
pathological scoring criteria [7]. Active renal lesions,
as assessed by the presence of crescents and ﬁbrinoid
necrosis and interstitial inﬁltrates, were similar in all
serological subgroups (Figure 2a).
Severe interstitial ﬁbrosis and glomerulosclerosis
were more prominent in ANCA-negative and MPO-
positive patients compared with PR3-positive patients
(see Figure 2a and b).
A possible explanation is that MPO-positive and
ANCA-negative disease might be entities that lead
to rapid progression of irreversible renal lesions. It is
more likely, that in patients with MPO-positive or
ANCA-negative vasculitis, a delay in diagnosis exposes
the kidney to a chronic smouldering disease activity.
Ultimately, a large amount of interstitial ﬁbrosis
representing chronic renal damage may be the result.
ANCA-negative renal vasculitis is also characterized
by glomerular inﬁltrating cells in up to 80% of our
patients. Minor inﬁltrates of PN in glomerular capillary
loops were observed in almost 40% of all biopsies,
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Fig. 2. Renal histology of ANCA-negative compared with MPO-
and PR3-ANCA-positive biopsies. (a) Glomerular lesions.
(b) Interstitial ﬁbrosis. (þMPO- and PR3-ANCA-positive groups
with permission from Hauer et al. [7]. #PR3-positive vs MPO-
positive or vs ANCA-negative P<0.05 for glomerulosclerosis.
*PR3-positive vs MPO-positive or vs ANCA-negative P<0.05).
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mainly in necrotic lesions. Additionally, we observed
moderate to severe interstitial inﬁltrates in 45% of
the biopsies, predominantly a mixed inﬁltrate of
lymphocytes and macrophages with signiﬁcant pres-
ence of PN. Weidner et al. [21] identiﬁed a comparable
composition of cellular inﬁltrates in a careful analysis
of 65 biopsies from ANCA-associated renal vasculitis.
The mechanisms leading to the occurrence of
ANCA-negative vasculitis are unclear. In ANCA-
positive vasculitis, these auto-antibodies activate
neutrophils by different mechanisms (e.g. direct Fab02
binding to ANCA antigens on leukocyte surfaces, or Fc
receptor engagement by ANCA immune complexes)
leading to neutrophil and endothelial cell apoptosis
and necrosis [6]. However, in ANCA-negative disease,
the presence of PN in pathological lesions occurs
independently of circulating ANCAs, and may involve
other unidentiﬁed autoantibodies or T-cell-dependent
mechanisms [22].
The mortality rate of our ANCA-negative cohort
is 35% over 5 years. In ANCA-positive vasculitis,
mortality rates vary from 24 to 41% [3,23,24]. Patient
survival was strongly correlated with age in our cohort,
which has been already shown for ANCA-associated
vasculitis [23,24]. Apparently, co-morbidity from
cardiovascular disease and infectious complications
due to immunosuppressive therapy accounts for the
high mortality rate in older patients independently of
the ANCA status.
Renal outcome was related to initial serum creatinine
and to DEI, but not to any of the evaluated histological
parameters. However, the amount of glomerular ﬁbri-
noid necrosis had a tendency to correlate positively
with the improvement of renal function in our study.
A recent European multicentre study in 160 patients
with ANCA-associated vasculitis identiﬁed serum
creatinine at presentation as the best predictor of
renal function after 1 year [25]. Histological para-
meters, like the amount of normal glomeruli and
ﬁbrinoid necrosis, are correlated with renal outcome
in ANCA-associated vasculitis [26]. Our failure to
show any ﬁrm relationship between histological
markers and renal outcome in ANCA-negative disease
may be due to the limited size of our cohort.
In conclusion, pauci-immune crescentic necrotizing
GN can in the absence of ANCAs but with clinical
and histological ﬁndings indistinguishable from
ANCA-associated vasculitis. Renal histology shows
extensive chronic renal damage as found in MPO-
positive vasculitis.
The initial creatinine, DEI and age are useful
parameters for predicting renal or patient outcome
in ANCA-negative vasculitis. Our ﬁnding of a high
mortality rate, especially in older patients, underlines
the importance of an exact diagnosis in the absence
of ANCAs. Neutrophils may play a pathogenic role
even in the absence of ANCAs, although the mechan-
ism of neutrophil activation remains to be elucidated.
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